Skip to main content

Articles

Page 1 of 104

  1. The role of parathyroid hormone (PTH)-related protein (PTHrP) in breast cancer remains controversial, with reports of PTHrP inhibiting or promoting primary tumor growth in preclinical studies. Here, we provide...

    Authors: Courtney M. Edwards, Jeremy F. Kane, Jailyn A. Smith, Déja M. Grant, Jasmine A. Johnson, Maria A. Hernandez Diaz, Lawrence A. Vecchi III, Kai M. Bracey, Tolu N. Omokehinde, Joseph R. Fontana, Breelyn A. Karno, Halee T. Scott, Carolina J. Vogel, Jonathan W. Lowery, T. John Martin and Rachelle W. Johnson
    Citation: Breast Cancer Research 2024 26:34
  2. Estrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is the most effective and the standard first-line drug. However, its efficac...

    Authors: Ting Song, Hong Zhang, Qicheng Zhao, Zhiyuan Hu, Ziqian Wang, Yang Song and Zhichao Zhang
    Citation: Breast Cancer Research 2024 26:33
  3. Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that z...

    Authors: Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf II, Karen Messer, Catriona Jamieson, Thomas J. Kipps…
    Citation: Breast Cancer Research 2024 26:32
  4. Accurate classification of breast cancer molecular subtypes is crucial in determining treatment strategies and predicting clinical outcomes. This classification largely depends on the assessment of human epide...

    Authors: Minsun Jung, Seung Geun Song, Soo Ick Cho, Sangwon Shin, Taebum Lee, Wonkyung Jung, Hajin Lee, Jiyoung Park, Sanghoon Song, Gahee Park, Heon Song, Seonwook Park, Jinhee Lee, Mingu Kang, Jongchan Park, Sergio Pereira…
    Citation: Breast Cancer Research 2024 26:31
  5. Overexpression of prostate-specific membrane antigen (PSMA) on the vasculature of triple-negative breast cancer (TNBC) presents a promising avenue for targeted endogenous radiotherapy with [177Lu]Lu-PSMA-I&T. Thi...

    Authors: Amelie Heesch, Alexandru Florea, Jochen Maurer, Pardes Habib, Laura S. Werth, Thomas Hansen, Elmar Stickeler, Sabri E. M. Sahnoun, Felix M. Mottaghy and Agnieszka Morgenroth
    Citation: Breast Cancer Research 2024 26:30
  6. Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological complete respo...

    Authors: Françoise Derouane, Manon Desgres, Camilla Moroni, Jérôme Ambroise, Martine Berlière, Mieke R. Van Bockstal, Christine Galant, Cédric van Marcke, Marianela Vara-Messler, Stefan J. Hutten, Jos Jonkers, Larissa Mourao, Colinda L. G. J. Scheele, Francois P. Duhoux and Cyril Corbet
    Citation: Breast Cancer Research 2024 26:29
  7. Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational ...

    Authors: Claire Scheffges, Jérôme Devy, Jérôme Giustiniani, Stessy Francois, Lucille Cartier, Yacine Merrouche, Arnaud Foussat, Stéphane Potteaux, Armand Bensussan and Anne Marie-Cardine
    Citation: Breast Cancer Research 2024 26:28
  8. A malignancy might be found at surgery in cases of atypical ductal hyperplasia (ADH) diagnosed via US-guided core needle biopsy (CNB). The objective of this study was to investigate the diagnostic performance ...

    Authors: Jun Kang Li, Zhi Ying Jin, Yong Jie Xu, Nai Qin Fu, Ying Jiang, Shi Yu Li, Rui Lan Niu, Gang Liu and Zhi Li Wang
    Citation: Breast Cancer Research 2024 26:27
  9. MRI-based tumor shrinkage patterns (TSP) after neoadjuvant therapy (NAT) have been associated with pathological response. However, the understanding of TSP after early NAT remains limited. We aimed to analyze ...

    Authors: Mengfan Wang, Siyao Du, Si Gao, Ruimeng Zhao, Shasha Liu, Wenhong Jiang, Can Peng, Ruimei Chai and Lina Zhang
    Citation: Breast Cancer Research 2024 26:26
  10. There is increasing evidence that artificial intelligence (AI) breast cancer risk evaluation tools using digital mammograms are highly informative for 1–6 years following a negative screening examination. We h...

    Authors: Ruggiero Santeramo, Celeste Damiani, Jiefei Wei, Giovanni Montana and Adam R. Brentnall
    Citation: Breast Cancer Research 2024 26:25
  11. Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer tumorigenesis. We aimed to investigate the prognostic significance of manual sco...

    Authors: Caroline Rönnlund, Emmanouil G. Sifakis, Caroline Schagerholm, Qiao Yang, Emelie Karlsson, Xinsong Chen, Theodoros Foukakis, Jodi Weidler, Michael Bates, Irma Fredriksson, Stephanie Robertson and Johan Hartman
    Citation: Breast Cancer Research 2024 26:24
  12. The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the h...

    Authors: Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar and Powel H. Brown
    Citation: Breast Cancer Research 2024 26:23
  13. One major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contributes to ~ 30% of all breast cancer. Prevention targeting dense breast tissue has the ...

    Authors: Peter Lundberg, Annelie Abrahamsson, Johan Kihlberg, Jens Tellman, Ieva Tomkeviciene, Anette Karlsson, Maria Kristoffersen Wiberg, Marcel Warntjes and Charlotta Dabrosin
    Citation: Breast Cancer Research 2024 26:22
  14. Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. ...

    Authors: Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson…
    Citation: Breast Cancer Research 2024 26:20
  15. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated with a high relapse rate and poor prognosis. ADAMTS18 is proposed as an i...

    Authors: Jiahui Nie, Suying Dang, Rui Zhu, Tiantian Lu and Wei Zhang
    Citation: Breast Cancer Research 2024 26:19
  16. Since breast cancer patients respond diversely to immunotherapy, there is an urgent need to explore novel biomarkers to precisely predict clinical responses and enhance therapeutic efficacy. The purpose of our...

    Authors: Xiaorui Han, Yuan Guo, Huifen Ye, Zhihong Chen, Qingru Hu, Xinhua Wei, Zaiyi Liu and Changhong Liang
    Citation: Breast Cancer Research 2024 26:18
  17. Histological grade is a well-known prognostic factor that is routinely assessed in breast tumours. However, manual assessment of Nottingham Histological Grade (NHG) has high inter-assessor and inter-laboratory...

    Authors: Abhinav Sharma, Philippe Weitz, Yinxi Wang, Bojing Liu, Johan Vallon-Christersson, Johan Hartman and Mattias Rantalainen
    Citation: Breast Cancer Research 2024 26:17
  18. Contralateral breast cancer (CBC) is the most common second primary cancer diagnosed in breast cancer survivors, yet the understanding of the genetic susceptibility of CBC, particularly with respect to common ...

    Authors: Xiaohui Sun, Anne S. Reiner, Anh Phong Tran, Gordon P. Watt, Jung Hun Oh, Lene Mellemkjær, Charles F. Lynch, Julia A. Knight, Esther M. John, Kathleen E. Malone, Xiaolin Liang, Meghan Woods, Andriy Derkach, Patrick Concannon, Jonine L. Bernstein and Xiang Shu
    Citation: Breast Cancer Research 2024 26:16
  19. The birth cohort effect has been suggested to influence the rate of breast cancer incidence and the trends of associated reproductive and lifestyle factors. We conducted a cohort study to determine whether a d...

    Authors: Salma Nabila, Ji-Yeob Choi, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Aesun Shin, Melissa A. Merritt, Ryoko Katagiri, Xiao-Ou Shu, Norie Sawada, Akiko Tamakoshi, Ritsu Sakata, Atsushi Hozawa, Jeongseon Kim, Chisato Nagata…
    Citation: Breast Cancer Research 2024 26:15
  20. This study aimed to investigate the contralateral breast cancer (CBC) recurrence rate in Korean breast cancer patients according to their BRCA1/2 germline mutation status, focusing particularly on the CBC recurre...

    Authors: Eunhye Kang, Ji-Jung Jung, Changjin Lim, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han and Hyeong-Gon Moon
    Citation: Breast Cancer Research 2024 26:14
  21. Endocrine therapy resistance in hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) is a significant clinical challenge that poses several unmet needs in the management of the disease. This ...

    Authors: Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park and Yoon-La Choi
    Citation: Breast Cancer Research 2024 26:13
  22. Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30–40% of TNBC patients treated with neoadjuvant chemotherapy (N...

    Authors: Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong and Ritu Aneja
    Citation: Breast Cancer Research 2024 26:12
  23. Human breast cancer most frequently originates within a well-defined anatomical structure referred to as the terminal duct lobular unit (TDLU). This structure is endowed with its very own lobular fibroblasts r...

    Authors: Mikkel Morsing Bagger, Jonas Sjölund, Jiyoung Kim, Katharina Theresa Kohler, René Villadsen, Abbas Jafari, Moustapha Kassem, Kristian Pietras, Lone Rønnov-Jessen and Ole William Petersen
    Citation: Breast Cancer Research 2024 26:11
  24. Triple-negative breast cancer (TNBC) remains the most challenging subtype of breast cancer and lacks definite treatment targets. Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to ...

    Authors: Zi-Mei Peng, Xiao-Jian Han, Tao Wang, Jian-Jun Li, Chun-Xi Yang, Fang-Fang Tou and Zhen Zhang
    Citation: Breast Cancer Research 2024 26:10
  25. This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab.

    Authors: Nianhua Ding, Jian Pang, Xuan Liu, Xiongbin He, Wei Zhou, Haiqing Xie, Jianqi Feng, Guo Wang, Jie Tang, Jing Cao, Liying He, Yingjian He, Shouman Wang and Zhi Xiao
    Citation: Breast Cancer Research 2024 26:9
  26. To understand the dynamics that limit use of risk-management options by women at high risk of breast cancer, there is a critical need for research that focuses on patient perspectives. Prior research has left ...

    Authors: Tasleem J. Padamsee, Christina Bijou, Paige Swinehart-Hord, Megan Hils, Anna Muraveva, Rachel J. Meadows, Kate Shane-Carson, Lisa D. Yee, Celia E. Wills and Electra D. Paskett
    Citation: Breast Cancer Research 2024 26:8
  27. Generalizability of predictive models for pathological complete response (pCR) and overall survival (OS) in breast cancer patients requires diverse datasets. This study employed four machine learning models to...

    Authors: Kevin Dell’Aquila, Abhinav Vadlamani, Takouhie Maldjian, Susan Fineberg, Anna Eligulashvili, Julie Chung, Richard Adam, Laura Hodges, Wei Hou, Della Makower and Tim Q. Duong
    Citation: Breast Cancer Research 2024 26:7
  28. Reports of dual carriers of pathogenic BRCA1 variants in trans are extremely rare, and so far, most individuals have been associated with a Fanconi Anemia-like phenotype.

    Authors: Ines Block, Àngels Mateu-Regué, Thi Tuyet Nhu Do, Ieva Miceikaite, Daniel Sdogati, Martin J. Larsen, Qin Hao, Henriette Roed Nielsen, Susanne E. Boonen, Anne-Bine Skytte, Uffe Birk Jensen, Louise K. Høffding, Arcangela De Nicolo, Alessandra Viel, Emma Tudini, Michael T. Parsons…
    Citation: Breast Cancer Research 2024 26:6
  29. Triple-negative breast cancer (TNBC) is highly aggressive with limited available treatments. Stromal cells in the tumor microenvironment (TME) are crucial in TNBC progression; however, understanding the molecu...

    Authors: Stephanie J. Hachey, Christopher J. Hatch, Daniela Gaebler, Aneela Mocherla, Kevin Nee, Kai Kessenbrock and Christopher C. W. Hughes
    Citation: Breast Cancer Research 2024 26:5
  30. Dysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therap...

    Authors: Eike-Benjamin Braune, Felix Geist, Xiaojia Tang, Krishna Kalari, Judy Boughey, Liewei Wang, Roberto A. Leon-Ferre, Antonino B. D’Assoro, James N. Ingle, Matthew P. Goetz, Julian Kreis, Kang Wang, Theodoros Foukakis, Anita Seshire, Dirk Wienke and Urban Lendahl
    Citation: Breast Cancer Research 2024 26:4
  31. Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) /HER2-negative (HER2-) breast cancer allows real-time evaluation of drug efficacy as well as investigation of the biological and molecul...

    Authors: Joanna I. López-Velazco, Sara Manzano, María Otaño, Kepa Elorriaga, Núria Bultó, Julio Herrero, Ainhara Lahuerta, Virginia Segur, Isabel Álvarez-López, Maria M. Caffarel and Ander Urruticoechea
    Citation: Breast Cancer Research 2024 26:3
  32. Previous work in European ancestry populations has shown that adding a polygenic risk score (PRS) to breast cancer risk prediction models based on epidemiologic factors results in better discriminatory perform...

    Authors: Gary R. Zirpoli, Ruth M. Pfeiffer, Kimberly A. Bertrand, Dezheng Huo, Kathryn L. Lunetta and Julie R. Palmer
    Citation: Breast Cancer Research 2024 26:2
  33. Despite radiotherapy ability to significantly improve treatment outcomes and survival in triple-negative breast cancer (TNBC) patients, acquired resistance to radiotherapy poses a serious clinical challenge. P...

    Authors: Jinqiu Tao, Cailin Xue, Meng Cao, Jiahui Ye, Yulu Sun, Hao Chen, Yinan Guan, Wenjie Zhang, Weijie Zhang and Yongzhong Yao
    Citation: Breast Cancer Research 2024 26:1
  34. Allostatic load (AL) reflects the collective load of chronic stress during lifetime. Previous studies have shown that higher AL is associated with poor clinical outcomes among breast cancer patients. However, ...

    Authors: Yufan Guan, Jie Shen, Juan Lu, Bernard F. Fuemmeler, Lisa S. Shock and Hua Zhao
    Citation: Breast Cancer Research 2023 25:155
  35. The role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its association with survival outcomes in advanced HER2-positive breast cancer tre...

    Authors: Jeongmin Seo, Jiwon Koh, Dae-Won Lee, Jinyong Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim and Seock-Ah Im
    Citation: Breast Cancer Research 2023 25:154
  36. Invasive lobular breast carcinomas (ILC) have different histological features compared to non-special type carcinomas (NST), but the effect of histological subtypes on survival is controversial. In this study,...

    Authors: Davut Dayan, Stefan Lukac, Brigitte Rack, Florian Ebner, Visnja Fink, Elena Leinert, Kristina Veselinovic, Sabine Schütze, Ziad El Taie, Wolfgang Janni and Thomas W. P. Friedl
    Citation: Breast Cancer Research 2023 25:153
  37. The homologous recombination (HR) repair pathway for DNA damage, particularly the BRCA1 and BRCA2 genes, has become a target for cancer therapy, with poly ADP-ribose polymerase (PARP) inhibitors showing significa...

    Authors: Han-Fang Cheng, Yi-Fang Tsai, Chun-Yu Liu, Chih-Yi Hsu, Pei-Ju Lien, Yen-Shu Lin, Ta-Chung Chao, Jiun-I. Lai, Chin-Jung Feng, Yen-Jen Chen, Bo-Fang Chen, Jen-Hwey Chiu, Ling-Ming Tseng and Chi-Cheng Huang
    Citation: Breast Cancer Research 2023 25:152
  38. Triple-negative breast cancer (TNBC) represents the most challenging subtype of breast cancer. Studies have implicated an upregulation of lipid synthesis pathways in the initiation and progression of TNBC. Tar...

    Authors: Pan Hu, Peiyi Zhou, Tieyun Sun, Dingkang Liu, Jun Yin and Lubin Liu
    Citation: Breast Cancer Research 2023 25:151
  39. Epidemiologic data on insecticide exposures and breast cancer risk are inconclusive and mostly from high-income countries. Using data from 1071 invasive pathologically confirmed breast cancer cases and 2096 co...

    Authors: Naomie Olivos, Jim E. Banta, Rhonda Spencer-Hwang, Daniel Ansong, Laura E. Beane Freeman, Joe-Nat Clegg-Lamptey, Beatrice Wiafe-Addai, Lawrence Edusei, Ernest Adjei, Nicholas Titiloye, Florence Dedey, Francis Aitpillah, Joseph Oppong, Verna Vanderpuye, Ernest Osei-Bonsu, Thomas U. Ahearn…
    Citation: Breast Cancer Research 2023 25:150
  40. Based on the molecular expression of cancer cells, molecular subtypes of breast cancer have been applied to classify patients for predicting clinical outcomes and prognosis. However, further evidence is needed...

    Authors: Shih-Kai Hung, Hsuan-Ju Yang, Moon-Sing Lee, Dai-Wei Liu, Liang-Cheng Chen, Chia-Hui Chew, Chun-Hung Lin, Cheng-Hung Lee, Szu-Chin Li, Chung-Lin Hong, Chih-Chia Yu, Ben-Hui Yu, Feng-Chun Hsu, Wen-Yen Chiou and Hon-Yi Lin
    Citation: Breast Cancer Research 2023 25:149
  41. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and leads to the poorest patient outcomes despite surgery and chemotherapy treatment. Exploring new molecular mechanisms of TNB...

    Authors: Zheqiong Tan, Pragney Deme, Keerti Boyapati, Britt S. R. Claes, Annet A. M. Duivenvoorden, Ron M. A. Heeren, Caitlin M. Tressler, Norman James Haughey and Kristine Glunde
    Citation: Breast Cancer Research 2023 25:148
  42. Women with dense breasts have an increased risk of breast cancer. However, breast density is measured with variability, which may reduce the reliability and accuracy of its association with breast cancer risk....

    Authors: Emma C. Atakpa, Diana S. M. Buist, Erin J. Aiello Bowles, Jack Cuzick and Adam R. Brentnall
    Citation: Breast Cancer Research 2023 25:147
  43. In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics which prohibit clinical response to anti-HER2 therapies and drive diseas...

    Authors: Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting and John W. M. Martens
    Citation: Breast Cancer Research 2023 25:145
  44. Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to relapse and progression. Super-enhancers are regulators of stemness, and BET proteins, wh...

    Authors: Deeksha Sharma, Cody G. Hager, Li Shang, Lam Tran, Yongyou Zhu, Aihui Ma, Brian Magnuson, Matthew W. Lesko, Max S. Wicha and Monika L. Burness
    Citation: Breast Cancer Research 2023 25:144
  45. As in most solid cancers, the emergence of cells with oncogenic mutations in the mammary epithelium alters the tissue homeostasis. Some soluble factors, such as TGFβ, potently modify the behavior of healthy st...

    Authors: Héctor Franco-Valls, Elsa Tusquets-Uxó, Laura Sala, Maria Val, Raúl Peña, Alessandra Iaconcig, Álvaro Villarino, Martín Jiménez-Arriola, Pere Massó, Juan L. Trincado, Eduardo Eyras, Andrés F. Muro, Jorge Otero, Antonio García de Herreros and Josep Baulida
    Citation: Breast Cancer Research 2023 25:143
  46. Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent nee...

    Authors: Witali Aswolinskiy, Enrico Munari, Hugo M. Horlings, Lennart Mulder, Giuseppe Bogina, Joyce Sanders, Yat-Hee Liu, Alexandra W. van den Belt-Dusebout, Leslie Tessier, Maschenka Balkenhol, Michelle Stegeman, Jeffrey Hoven, Jelle Wesseling, Jeroen van der Laak, Esther H. Lips and Francesco Ciompi
    Citation: Breast Cancer Research 2023 25:142
  47. Window-of-opportunity (WOO) studies provide insights into the clinical activity of new drugs in breast cancer.

    Authors: Mario Campone, François-Clément Bidard, Patrick Neven, Lei Wang, Bin Ling, Yvonne Dong, Gautier Paux, Christina Herold and Ugo De Giorgi
    Citation: Breast Cancer Research 2023 25:141

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2022 Speed
    27 days submission to first editorial decision for all manuscripts (Median)
    166 days submission to accept (Median)

    2022 Usage 
    2,233,470 downloads
    8,627 Altmetric mentions